The Diagnosis and Treatment of MF and PV: Where Are We and Where Are We Going?

/ Print /
| ShareMore
/ Text Size +
12/10/21 11:00 am EDT
Hyatt Regency Atlanta + Live Streaming
265 Peachtree St NE
Atlanta, GA
United States

The myeloproliferative neoplasms, such as polycythemia vera (PV) and myelofibrosis (MF), are hematologic cancers affecting the bone marrow that lead to debilitating symptoms and reduced survival. Managing these cancers requires careful assessment of risk, management of symptoms, and prevention of serious or fatal complications. In recent years, research has been focused on improving risk stratification and treatment options to help manage symptoms and modify disease biology.

Learning Objectives

The learning objectives of this program are:

  • Determine the impact of genetics, symptom burden and risk stratification on therapy selection in MPN
  • Evaluate the clinical profiles of current and emerging therapeutic strategies in MPN across therapy lines
  • Apply proactive strategies to identify and manage disease-associated symptoms and treatment-related toxicities in patients with MPN
  • Translate updated clinical trial evidence and guidelines into personalized treatment plans for patients with MPN, with a focus on care optimization across the disease continuum


Friday, December 10, 2021

Registration and Brunch: 10:15 AM – 11:00 AM

Scientific Session: 11:00 AM – 2:00 PM



Hyatt Regency Atlanta

In-Person and Livestreaming Satellite Symposium


Program Chair


Srdan Verstovsek, MD, PhD
United Energy Resources, Inc. Professor of Medicine
Founder and Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
MD Anderson Cancer Center
Houston, TX